Sex-Based Transcriptomic Variations in Schizophrenia: Prospects for Targeted Therapy
DOI:
https://doi.org/10.46570/utjms-2025-1899Keywords:
schizophrenia, Drug repurposing, RNAseq, sex differences, pathway analysisAbstract
Schizophrenia is a complex neuropsychiatric disorder with significant sex differences in onset, symptoms, and outcomes, suggesting that biological sex may influence disease mechanisms. However, molecular differences between males and females with schizophrenia remain poorly defined. This study examined sex-specific transcriptional alterations in the dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia using publicly available RNA-sequencing data (GSE144136). Differential gene expression (DGE) analyses were performed separately for male and female cohorts, followed by gene set enrichment analysis (GSEA), leading-edge (LE) gene analysis, and perturbagen signature matching using the Library of Integrated Network-Based Cellular Signatures (iLINCS). No genes reached significance after correction, but unadjusted analyses revealed marked sex differences. Using the uncorrected analysis, Males exhibited over 2,000 differentially expressed genes distributed evenly between up- and downregulation, whereas females showed a smaller set of differentially expressed genes that were skewed towards upregulation. Pathway-level analyses showed that males displayed upregulation of metabolic pathways and downregulation of synaptic transport processes, while females exhibited upregulation of immune pathways alongside downregulation of vesicle organization and phosphoinositide metabolism. LE gene analysis supported the pathway changes. iLINCS analysis further highlighted sex-specific drug candidates whose expression profiles were discordant schizophrenia-associated signatures. FDA approved medications with high discordance included JAK2/mTOR pathway inhibitors and metabolic regulators in males, and immune or hormonal modulators in females. Taken together, these results reveal divergent molecular signatures that may underlie sex differences in schizophrenia pathophysiology. The identification of candidate drugs with discordant transcriptomic effects suggests potential therapeutic avenues and emphasizes the importance of sex stratified approaches in schizophrenia research.
References
Saha, S., D. Chant, and J. McGrath, A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry, 2007. 64(10): p. 1123-31.
Giordano, G.M., et al., Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. Front Psychiatry, 2021. 12: p. 789179.
Ochoa, S., et al., Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment, 2012. 2012: p. 916198.
Khandaker, G.M., et al., Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry, 2015. 2(3): p. 258-270.
Salter, M.W. and B. Stevens, Microglia emerge as central players in brain disease. Nat Med, 2017. 23(9): p. 1018-1027.
Lisman, J.E., et al., Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci, 2008. 31(5): p. 234-42.
Nagy, C., et al., Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nat Neurosci, 2020. 23(6): p. 771-781.
Shi, J. and M.G. Walker, Gene set enrichment analysis (GSEA) for interpreting gene expression profiles. Current Bioinformatics, 2007. 2(2): p. 133-137.
Koleti, A., et al., Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data. Nucleic Acids Res, 2018. 46(D1): p. D558-D566.
Robinson, M.D., D.J. McCarthy, and G.K. Smyth, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 2010. 26(1): p. 139-40.
Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 15545-50.
Kurita, M., et al., HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neuroscience, 2012. 15(9): p. 1245-1254.
Martínez-Peula, O., et al., A method for HDAC activity screening in postmortem human brain. A proof-of-concept study with antipsychotics. Journal of Neuroscience Methods, 2025. 416: p. 110365.
Kim, Y. and S. Kim, Target Discovery Using Deep Learning-Based Molecular Docking and Predicted Protein Structures With AlphaFold for Novel Antipsychotics. Psychiatry Investig, 2023. 20(6): p. 504-514.
Ximenis, M., et al. Natural Polyhydroxy Flavonoids, Curcuminoids, and Synthetic Curcumin Analogs as ?7 nAChRs Positive Allosteric Modulators. International Journal of Molecular Sciences, 2021. 22, DOI: 10.3390/ijms22020973.
A heritable disorder of lithium transport in erythrocytes of a subpopulation of manic-depressive patients. American Journal of Psychiatry, 1978. 135(9): p. 1070-1078.
Benoit, C.-E., et al., Loss of Quinone Reductase 2 Function Selectively Facilitates Learning Behaviors. The Journal of Neuroscience, 2010. 30(38): p. 12690.
Asit, K.C., et al., Progress in COX-2 Inhibitors: A Journey So Far. Current Medicinal Chemistry, 2010. 17(15): p. 1563-1593.
Wang, X., et al., The relationship between alterations in plasma metabolites and treatment responses in antipsychotic-naïve female patients with schizophrenia. The World Journal of Biological Psychiatry, 2024. 25(2): p. 106-115.
Zhuo, C., et al., Acid sphingomyelinase/ceramide system in schizophrenia: implications for therapeutic intervention as a potential novel target. Translational Psychiatry, 2022. 12(1): p. 260.
Mohammed, A., et al., Rosuvastatin improves olanzapine’s effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats. Behavioural Brain Research, 2020. 378: p. 112305.
Siwek, M., et al., Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacological Reports, 2020. 72(2): p. 350-359.
Yoshida, Y., et al., Selective and competitive inhibition of kynurenine aminotransferase 2 by glycyrrhizic acid and its analogues. Scientific Reports, 2019. 9(1): p. 10243.
Williams, O.O.F., et al., Sex Differences in Dopamine Receptors and Relevance to Neuropsychiatric Disorders. Brain Sci, 2021. 11(9).
Mayer, F.P., A. Stewart, and R.D. Blakely, Leaky lessons learned: Efflux prone dopamine transporter variant reveals sex and circuit specific contributions of D2 receptor signalling to neuropsychiatric disease. Basic Clin Pharmacol Toxicol, 2024. 134(2): p. 206-218.
Carceller, H., et al., The impact of sex on gene expression in the brain of schizophrenic patients: a systematic review and meta-analysis of transcriptomic studies. Biol Sex Differ, 2024. 15(1): p. 59.
Ermakov, E.A., et al., Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review. Int J Mol Sci, 2023. 24(3).
Ermakov, E.A., et al., Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives. Front Psychiatry, 2022. 13: p. 880568.
Jones, A.L., et al., Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol Cell Biol, 2005. 83(1): p. 9-17.
Michel, M., M.J. Schmidt, and K. Mirnics, Immune system gene dysregulation in autism and schizophrenia. Dev Neurobiol, 2012. 72(10): p. 1277-87.
Strous, R.D. and Y. Shoenfeld, Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun, 2006. 27(2): p. 71-80.
Yu, S., et al., The expression of immune related genes and potential regulatory mechanisms in schizophrenia. Schizophr Res, 2024. 267: p. 507-518.
Bryll, A., et al., Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia. Biomolecules, 2020. 10(3).
Fizíková, I., J. Dragašek, and P. Ra?ay, Mitochondrial Dysfunction, Altered Mitochondrial Oxygen, and Energy Metabolism Associated with the Pathogenesis of Schizophrenia. Int J Mol Sci, 2023. 24(9).
Konradi, C. and D. Öngür, Role of mitochondria and energy metabolism in schizophrenia and psychotic disorders. Schizophr Res, 2017. 187: p. 1-2.
Pruett, B.S. and J.H. Meador-Woodruff, Evidence for altered energy metabolism, increased lactate, and decreased pH in schizophrenia brain: A focused review and meta-analysis of human postmortem and magnetic resonance spectroscopy studies. Schizophr Res, 2020. 223: p. 29-42.
Steen, N.E., et al., Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. Psychol Med, 2020. 50(4): p. 595-606.
de la Fuente Revenga, M., et al., HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice. Neuroscience, 2018. 388: p. 102-117.
Kennedy, A.J., et al., Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Rep, 2016. 16(10): p. 2666-2685.
Kurita, M., et al., HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci, 2012. 15(9): p. 1245-54.
Siwek, M., et al., Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacol Rep, 2020. 72(2): p. 350-359.
De Hert, M., et al., Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry, 2006. 67(12): p. 1889-96.
Mohammed, A., et al., Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats. Behav Brain Res, 2020. 378: p. 112305.
Shen, H., et al., Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications. Psychiatry Res, 2018. 262: p. 84-93.
Koike, S., et al., Plasma unconjugated bile acids as novel biomarker for schizophrenia. Biochem Biophys Res Commun, 2022. 634: p. 70-74.
Tao, Y., et al., A combination of three plasma bile acids as a putative biomarker for schizophrenia. Acta Neuropsychiatr, 2021. 33(1): p. 51-54.
Li, X., W. Zhou, and Z. Yi, A glimpse of gender differences in schizophrenia. Gen Psychiatr, 2022. 35(4): p. e100823.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Eire Chen, Jasleen Mann, Fred Muler, Henry Sun, Eleza Zaidi, Robert McCullumsmith, Jacob Schmieder, Hunter Eby (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
